Stay updated on Nivolumab Plus Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page
- ChecktodayChange DetectedThe study record no longer includes “2015 (U.S. NIH Grant/Contract)” among its related terms. The site revision marker changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe ClinicalTrials.gov record for the CheckMate 401 advanced melanoma study is displayed, including study design, participant criteria, locations, outcome measures, publications, and supporting documents. The record also indicates that the study is completed and no longer recruiting.SummaryDifference89%

- Check21 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA notice about NIH websites transitioning from the term “Artificial Intelligence” to “Super Intelligence” appears above the ClinicalTrials.gov page. The study record remains inaccessible with a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.